Disney Has Its CEO - motley-fool-money Recap

Podcast: motley-fool-money

Published: 2026-02-04

Duration: 18 minutes

Summary

Disney has appointed Josh D'Amaro as its new CEO, succeeding Bob Iger whose legacy includes major acquisitions and streaming profitability. The episode also analyzes Chipotle's earnings and the competitive dynamics in the GLP-1 market.

What Happened

Josh D'Amaro has been named the new CEO of Disney, taking over from Bob Iger in March. Iger is leaving behind a complex legacy, credited with transformative acquisitions like Pixar, Marvel, and Lucasfilm, which boosted Disney's market cap significantly. However, his second tenure saw challenges, including stabilizing streaming services and managing cost cuts amid a changing media landscape.

Bob Iger's leadership turned Disney's streaming segment from a loss-making venture to a profitable one, generating a billion dollars in profit. Despite this, Disney's stock performance has been stagnant, reflecting market concerns about its core television business.

With Josh D'Amaro stepping in, there are questions about whether Disney will face another transitional period similar to the one under Bob Chapek. The parks remain a crucial part of Disney's business, but the future of its linear networks and ESPN remains uncertain, with speculation about possible spin-offs.

Chipotle's recent earnings report showed a decline in transactions by 3.2% and a drop in operating margins, affected by rising costs and consumers pulling back on discretionary spending. Despite these challenges, Chipotle continues to expand aggressively, opening numerous new locations.

The fast-casual dining sector is facing broader industry headwinds, with consumers shifting preferences towards sit-down dining experiences or opting for more economical options like McDonald's. Chipotle's struggles seem to reflect this wider trend rather than company-specific issues.

The GLP-1 market, dominated by Novo Nordisk and Eli Lilly, is experiencing a shift as competitive pressures increase. Eli Lilly is performing well with a significant revenue increase, while Novo Nordisk faces challenges from patent expirations and increased competition from cheaper alternatives.

Key Insights